DPP-4 inhibitors did not lower the risk of any cardiorenal outcome when compared with placebo and were associated with higher risks of MACE, HHF, and renal outcome when compared with the other two drug classes
L.TennantD
More recently, there has been an unprecedented focus on new weight loss drugs with the same active ingredient: semaglutide
Balancing Rare Safety Signals With Proven Benefits of GLP-1 Medicines This large nationwide Swedish study adds important evidence to the ongoing evaluation of the long-term safety of GLP-1 receptor agonists
Going beyond two tablespoons doesnt increase the effect and raises the risk of stomach discomfort, low potassium, and enamel erosion
Westend Medical Supply does not manufacture, test, authenticate, or guarantee the quality or compatibility of any third-party peptide or compound used with our products